Skip to main content

Samsara BioCapital — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

132
Companies
$11.9B
Total invested
$118.5M
Avg. check
15
Industries
Biotechnology 22Health Care 15Therapeutics 12Biopharma 9Medical 9Pharmaceutical 7+9 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 132
EGenesis
September 2024

EGenesis is a gene editing and genome engineering company developing human-compatible engineered organs to treat diseases.

Biopharma · Cambridge$191.0M Series D
IO Biotech
September 2025

IO Biotech is a clinical-stage biotech company developing disruptive immune therapies for the treatment of cancer.

Biotechnology · Copenhagen$6.6M Post-IPO Equity
Pepgen
September 2025

PepGen is empowering nucleic acid therapeutics to go the distance.

Biotechnology · Oxford$115.0M Post-IPO Equity
HilleVax
September 2023

HilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines.

Biopharma · Boston$100.0M Post-IPO Equity
Allakos
September 2022

Allakos is a biotechnology company developing therapeutic antibodies targeting allergy, inflammatory and proliferative diseases.

Biopharma · Redwood City$150.0M Post-IPO Equity
ACELYRIN
September 2022

ACELYRIN is a biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing therapies.

Biopharma · Los Angeles$300.0M Series C
Seismic Therapeutic
September 2024

Seismic Therapeutic is a biotechnology company developing machine-learning technology for immunology drug development.

Biotechnology · Watertown$25.0M Series B
Neurogastrx
August 2021

A private biopharmaceutical company .

Biotechnology · Woburn$60.0M Series B
Pathalys Pharma
August 2024

Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease.

Biopharma · Raleigh$105.0M Series B
Abata Therapeutics
August 2024

Abata Therapeutics develops regulatory T cell (Treg) therapies for treating autoimmune diseases including progressive multiple sclerosis.

Biotechnology · CambridgeCorporate Round
Prime Medicine
August 2025

Prime Medicine is a biotechnology company that utilizes Prime Editing to modify genetic sequences to treat a wide range of diseases.

Biotechnology · Cambridge$5.0M Post-IPO Equity
Claris Biotherapeutics
July 2026

Claris Biotherapeutics develops biologic therapies for corneal diseases and other disorders affecting the ocular surface.

Biopharma · Jersey City$118.0M Series B
Autobahn Therapeutics
July 2024

Clinical stage biotechnology company developing restorative treatments for people affected by neuropsychiatric & neuroimmunologic disorders

Biotechnology · San Diego$100.0M Series C
Gossamer Bio
July 2023

Gossamer Bio is a biopharmaceutical company focused on the discovery and development of novel and differentiated therapeutic products.

Biotechnology · San Diego$212.0M Post-IPO Equity
DELFI Diagnostics
July 2022

DELFI's AI platform uses whole-genome sequencing to detect cancer-associated cfDNA fragmentation patterns in the blood.

Artificial Intelligence (AI) · Palo Alto$225.0M Series B
Jasper Therapeutics
July 2026

Jasper Therapeutics is a biotechnology company that develops novel antibody therapies for stem cell transplants.

Biotechnology · Redwood City$132.0M Post-IPO Equity
LENZ Therapeutics
July 2024

LENZ Therapeutics operates as an organization engaged in the late-stage clinical development of pharmaceuticals for the eyes.

Health Care · Del Mar$30.0M Post-IPO Equity
Neurogene
July 2026

Neurogene is a developer of genetic medicines intended to improve patient outcomes for neurological disorders.

Biotechnology · New York$125.0M Post-IPO Equity
Septerna
July 2023

Septerna is a biotech firm unlocking diverse drug discovery potential in G protein-coupled receptors across various diseases.

Biotechnology · San Francisco$150.0M Series B
Elevation Oncology
June 2023

Elevation Oncology is a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients.

Biopharma · New York$50.0M Post-IPO Equity
Upstream Bio
June 2023

Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma.

Biotechnology · Waltham$200.0M Series B
Jade Biosciences
June 2026

Jade Biosciences is developing transformative therapies to redefine the standard of care for inflammation and immunology indications.

Biopharma · Waltham$150.0M Post-IPO Equity
Mineralys Therapeutics
June 2026

Mineralys Therapeutics is a clinical-stage biopharmaceutical company committed to developing therapy for the treatment of hypertension.

Biopharma · Radnor$500.0M Post-IPO Debt
MiroBio
June 2022

MiroBio is Harnessing the natural control mechanisms of the immune system.

Biotechnology · Oxford$97.0M Series B

Where Samsara BioCapital invests

Biotechnology22
Health Care15
Therapeutics12
Biopharma9
Medical9
Pharmaceutical7

About Samsara BioCapital's portfolio

How many companies has Samsara BioCapital invested in?

Samsara BioCapital has invested in 132 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Samsara BioCapital invest in?

Samsara BioCapital's top investment sectors include Biotechnology, Health Care, Therapeutics, Biopharma, Medical. The firm invests across 15 different industry categories.

What is Samsara BioCapital's largest investment?

Among tracked funding rounds, Mineralys Therapeutics received $500.0M in a Post-IPO Debt round. Samsara BioCapital's total known invested capital is $11.9B.

What is the average investment size for Samsara BioCapital?

Samsara BioCapital's average investment size is $118.5M across its portfolio of 132 companies.

What are Samsara BioCapital's most recent investments?

Recent Samsara BioCapital portfolio additions include EGenesis, IO Biotech, Pepgen, HilleVax, Allakos. These companies were founded in 2020 or later.

Reach the founders behind these 132 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →